Clinical trials
B Cell Malignancies clinical trials
Below are recruiting b cell malignancies clinical trials, each written for real people, not researchers. We’re tracking 604 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07219576RecruitingPhase 1/Phase 2
Study of Retifanlimab and Ruxolitinib for Certain Cancers
This trial tests a combination of two drugs, retifanlimab and ruxolitinib, for people with advanced kidney cancer (clear cell renal cell carcinoma) or lung cancer (non-small cell lung carcinoma) whose cancer has grown after previous treatment with a type of immunotherapy called PD-1/PD-L1 inhibitors. The goal is to see if this combination can help when standard treatments are no longer working.
La Jolla, CaliforniaAges Any age - NCT06393738RecruitingPhase 1
ARV-393 for relapsed or refractory non-Hodgkin lymphoma
This study tests a new oral medication (ARV-393) for people with certain types of non-Hodgkin lymphoma that have returned or not responded to previous treatments. The drug is designed to target a protein inside cancer cells to make them stop growing and die.
New Haven, ConnecticutAges 18 years+ - NCT05389423RecruitingPhase 1
Pomalidomide plus chemotherapy for HIV-related lymphoma
This Phase 1 study tests whether a combination of pomalidomide and a dose-adjusted chemotherapy plan (EPOCH), with or without rituximab, can treat certain aggressive B-cell lymphomas in people living with HIV. It aims to find a safe dosing approach and see how well the treatment works for specific lymphoma types or high risk of spread to the brain.
Bethesda, MarylandAges 18–120 - NCT06615193RecruitingPhase 1
Testing a new drug for certain blood and solid tumors
This study tests a new drug, HDM2005, for people with relapsed or hard-to-treat B-cell lymphoma or advanced solid tumors. The goal is to see if it is safe and effective.
Zhengzhou, HenanAges 18 years+ - NCT07752953Recruiting
Personalized immune cell therapy for solid tumors
This trial tests a personalized cancer vaccine made from your own immune cells to help your body fight the tumor. It is for people with solid tumors that have not responded to other treatments.
Qinhuangdao, HebeiAges 18–75 - NCT05702853RecruitingPhase 1/Phase 2
CAR T-cell therapy after CD34 selection for CD19 lymphoma or CLL
This Phase 1/2 study tests a customized type of immune cell treatment (CD19 CAR T-cells) for people with certain relapsed or hard-to-treat lymphomas or CLL/SLL. It aims to improve control of disease by targeting the CD19 marker on cancer cells.
Charleston, South CarolinaAges 18 years+ - NCT07779018RecruitingPhase 2
CAR-T cell therapy after second-line treatment for aggressive B-cell lymphoma
This trial tests a type of immunotherapy called CAR-T cell therapy, which uses your own immune cells to fight lymphoma. It is for people who have already responded well to a second round of chemotherapy and are at high risk of the cancer coming back. The goal is to see if this treatment can keep the cancer away longer.
BeijingAges 18–85 - NCT02727803RecruitingPhase 2
Personalized natural killer cell therapy for blood cancers
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
Houston, TexasAges 15–80 - NCT06728189RecruitingPhase 1
CD70-targeted CAR-NKT cells for advanced solid tumors
This trial tests a new type of immune cell therapy (CAR-NKT cells) that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to at least two prior treatments.
BeijingAges 18–75 - NCT05312801RecruitingPhase 1
Testing BAFF CAR-T for relapsed or resistant non-Hodgkin lymphoma
This Phase 1 study tests a new immune cell treatment (BAFF CAR-T) for people with non-Hodgkin lymphoma that has come back or did not respond well to treatment. It aims to see how safe it is and whether it can help control the lymphoma.
Cleveland, OhioAges 18 years+ - NCT06625190RecruitingPhase 1/Phase 2
Half-matched transplant with zoledronic acid for resistant solid tumors
This trial tests a new approach using a special type of transplant (with cells from a half-matched family donor) plus a drug called zoledronic acid. It is for children and young adults with certain solid tumors that have not responded to standard treatments.
Gainesville, FloridaAges 6 months–25 years - NCT06484920RecruitingPhase 2
Pembrolizumab and ATRA for relapsed lymphoma
This trial tests a new combination of two medicines, pembrolizumab and ATRA (a form of vitamin A), for people with certain lymphomas that have come back or stopped responding to earlier treatments. The goal is to see if the combination can help the immune system fight the cancer more effectively.
Indianapolis, IndianaAges 18 years+ - NCT05054257RecruitingPhase 1
CAR T19 for hard-to-treat blood cancers that have CD19
This Phase 1 study tests CAR T cells designed to attack cancer cells that carry a marker called CD19. It’s for adults with certain relapsed or treatment-resistant B-cell leukemias (ALL) or lymphomas (NHL) where other treatments may not have worked.
PragueAges 18–80 - NCT07012980RecruitingPhase 2
Three-drug combination for first-line lymphoma in people 70 and older
This study tests a combination of three newer targeted drugs for older adults (70+) who have just been diagnosed with diffuse large B-cell lymphoma and have not yet received any treatment. The goal is to see if this drug combo can control the lymphoma effectively while being manageable for older patients.
Shanghai, Shanghai MunicipalityAges 70 years+ - NCT06717347RecruitingPhase 3
Study of a new drug combo for untreated DLBCL
This trial tests whether adding zilovertamab vedotin to standard chemo (R-CHP) works better than standard chemo (R-CHOP) for people with untreated diffuse large B-cell lymphoma (DLBCL). It aims to find a more effective treatment option.
Mobile, AlabamaAges 18 years+ - NCT07519772RecruitingPhase 1/Phase 2
Testing MK-1045 for Hard-to-Treat Lymphoma
This study tests a new drug called MK-1045 for people with follicular lymphoma or diffuse large B-cell lymphoma (two types of blood cancer) that hasn't responded to at least two previous treatments. The drug is designed to target cancer cells and may help people whose cancer has come back or stopped responding to therapy.
Los Angeles, CaliforniaAges 18 years+ - NCT03356054RecruitingPhase 1/Phase 2
Test drug for CD30-positive lymphoma after first treatment fails
This early-phase study tests a lymphoma treatment in adults whose diffuse large B-cell lymphoma (DLBCL) is “CD30-positive” and who didn’t respond well to first-line chemotherapy (like R-CHOP) or had an early relapse. It aims to see if the treatment can shrink the lymphoma and is safe enough to move forward.
RotterdamAges 18 years+ - NCT05040555Recruiting
Testing a new chemo plan for newly diagnosed high-burden lymphoma
This trial studies a specific treatment plan to see how well it works for adults with newly diagnosed non-Hodgkin lymphoma that has a high amount of disease. It may help by aiming to control lymphoma more effectively, especially when it is widespread.
Changchun, JilinAges 18–75 - NCT04442412RecruitingPhase 3
Prednisone and vitamin D before chemo for certain lymphomas
This Phase 3 study tests whether a short “pre-treatment” with prednisone, with or without vitamin D, can improve outcomes when followed by standard lymphoma chemo. It aims to see if adding vitamin D early can help older adults tolerate or benefit from treatment for specific lymphoma types.
Brescia, BSAges 65 years+ - NCT05831865Recruiting
Testing best first-line stem cell transplant for aggressive lymphoma
This trial studies the best way to use an early (frontline) stem cell transplant for high-risk, CD20-positive diffuse large B-cell lymphoma (DLBCL). It aims to improve outcomes by comparing treatment approaches designed for people with a higher risk score.
Beijing, Beijing MunicipalityAges 18–70 - NCT06176729RecruitingPhase 2
Pola-R2 for older, less fit adults with new DLBCL
This trial tests a combination of three drugs (pola, Rituxan, and lenalidomide) for older adults (70+) with a common type of lymphoma (DLBCL) who are not well enough for standard chemotherapy. The goal is to see if this gentler treatment works well for patients who are less fit.
Beijing, Beijing MunicipalityAges 70 years+ - NCT07817641Recruiting
Proton therapy for lymphoma in the chest
This trial tests proton therapy, a precise type of radiation, to treat lymphoma in the chest. The goal is to reduce damage to healthy organs while still curing the cancer.
Copenhagen, Select A StateAges 18 years+ - NCT06489808RecruitingPhase 2
Linperlisib plus chemoimmunotherapy for relapsed large B-cell lymphoma
This trial tests a drug called linperlisib combined with standard chemotherapy and immunotherapy for people with large B-cell lymphoma that has come back or not responded to one prior treatment.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06521255RecruitingPhase 3
New drug combo vs standard for relapsed DLBCL
This trial tests a new combination of drugs (tafasitamab + lenalidomide + gemcitabine + oxaliplatin) against a standard combination (rituximab + gemcitabine + oxaliplatin) for people with DLBCL that has returned or stopped responding to prior therapy. The goal is to see if the new combination works better.
BeijingAges 18 years+
Hear when a new B Cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for b cell malignancies?
- Yes. Clin2 currently lists 604 recruiting b cell malignancies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a b cell malignancies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a b cell malignancies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.